AR033832A1 - Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo - Google Patents

Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo

Info

Publication number
AR033832A1
AR033832A1 ARP010103870A ARP010103870A AR033832A1 AR 033832 A1 AR033832 A1 AR 033832A1 AR P010103870 A ARP010103870 A AR P010103870A AR P010103870 A ARP010103870 A AR P010103870A AR 033832 A1 AR033832 A1 AR 033832A1
Authority
AR
Argentina
Prior art keywords
antibody
peptide
drb1
mhc
antibodies
Prior art date
Application number
ARP010103870A
Other languages
English (en)
Inventor
Petrus Gerardus Antonius Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR033832A1 publication Critical patent/AR033832A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método ex vivo para diagnosticar una enfermedad autoinmune que comprende detectar la presencia de un complejo MHC-péptido específico autoinmune en un paciente que presenta una enfermedad autoinmune con anticuerpos o dominios que ligan antígenos de los mismos que se ligan específicamente a un complejo MHC-péptido derivado de HC-gp39. Anticuerpos monoclonales usados en el método; composición para diagnóstico que comprende uno o más de los anticuerpos y un agente de detección; uso del anticuerpo para la elaboración de un preparado farmacéutico para el tratamiento de trastornos autoinmunes; y uso del anticuerpo para la purificación de complejos MHC-péptido específicos autoinmunes. El complejo MHC-péptido a ser detectado de acuerdo con la presente invención se asocia con enfermedades autoinmunes, preferentemente con artritis reumatoide. Preferentemente, el complejo MHC es del tipo HLA DRB1*0401, DRB1*0404, DRB1*0407 y DRB1*0101 siendo el HLA DRB1*0401 es que más se prefiere mientras que el péptido en el complejo es preferentemente un antígeno asociado con artritis reumatoide. Preferentemente los anticuerpos son preparados usando complejos de péptidos derivados de HC gp-39. Preferentemente el péptido comprende los aminoácidos 263-273 o 263-275 de HC gp-39 (HC gp-39263-273 o HC gp-39263-275). Los anticuerpos también pueden ser usados para propósitos terapéuticos.
ARP010103870A 2000-08-14 2001-08-13 Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo AR033832A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00202844 2000-08-14

Publications (1)

Publication Number Publication Date
AR033832A1 true AR033832A1 (es) 2004-01-07

Family

ID=8171913

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103870A AR033832A1 (es) 2000-08-14 2001-08-13 Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo

Country Status (14)

Country Link
US (1) US7320873B2 (es)
EP (1) EP1319184B1 (es)
JP (1) JP2004506901A (es)
CN (1) CN1305906C (es)
AR (1) AR033832A1 (es)
AT (1) ATE368225T1 (es)
AU (2) AU2001293735B2 (es)
BR (1) BR0113213A (es)
CA (1) CA2415353A1 (es)
DE (1) DE60129572T2 (es)
ES (1) ES2290171T3 (es)
IL (2) IL154000A0 (es)
MX (1) MXPA03001391A (es)
WO (1) WO2002014870A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400659A3 (en) 2001-07-24 2005-06-28 Zhu Zhou Woodbridge Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2007030451A2 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
KR20090117878A (ko) * 2007-01-19 2009-11-13 카이 파마슈티컬즈 통증의 완화를 위한 엡실론 억제제 화합물의 사용 방법
WO2009151487A1 (en) * 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
US8673300B2 (en) 2009-06-04 2014-03-18 The Regents Of The University Of Colorado, A Body Corporate Therapeutic compositions and methods for the prevention of autoimmune diseases
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
WO2012007950A2 (en) * 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
EP2593551B1 (en) 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
EP2619579B1 (en) * 2010-09-21 2016-12-07 The General Hospital Corporation Diagnostic tests for immune reactivity with human endothelial cell growth factor
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
WO2012162697A1 (en) 2011-05-26 2012-11-29 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
AU2013326932B2 (en) 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
WO2015184203A1 (en) 2014-05-29 2015-12-03 Macrogenics, Inc. Tri-specific binding molecules and methods of use thereof
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
US9820957B2 (en) 2016-03-24 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmunity
MA47612A (fr) 2017-02-24 2020-01-01 Macrogenics Inc Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN111423504B (zh) * 2020-04-17 2021-03-26 安徽高安生物医学科技有限公司 黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE153695T1 (de) 1990-11-26 1997-06-15 Akzo Nobel Nv Verfahren zur herstellung von antikörpern
WO1995002188A1 (en) 1993-07-12 1995-01-19 The Regents Of The University Of California Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
CN1227263C (zh) * 1996-09-18 2005-11-16 格希尔德·韦尔纳 用于自身免疫性疾病的诊断及治疗的肽
IL122233A (en) 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
AU2001293735B2 (en) 2006-05-25
WO2002014870A3 (en) 2002-08-15
IL154000A0 (en) 2003-07-31
AU9373501A (en) 2002-02-25
CA2415353A1 (en) 2002-02-21
MXPA03001391A (es) 2004-05-04
CN1305906C (zh) 2007-03-21
US7320873B2 (en) 2008-01-22
ATE368225T1 (de) 2007-08-15
IL154000A (en) 2010-02-17
DE60129572T2 (de) 2008-04-17
BR0113213A (pt) 2003-07-08
US20040137514A1 (en) 2004-07-15
CN1447919A (zh) 2003-10-08
WO2002014870A2 (en) 2002-02-21
ES2290171T3 (es) 2008-02-16
JP2004506901A (ja) 2004-03-04
DE60129572D1 (de) 2007-09-06
EP1319184A2 (en) 2003-06-18
EP1319184B1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
AR033832A1 (es) Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo
Nossal et al. Antigens, lymphoid cells and the immune response
Spitler et al. Studies on the immune response to a characterized antigenic determinant of the tobacco mosaic virus protein
KR920700674A (ko) 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
BR9917218A (pt) Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
HUP0203705A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés kezelésére és diagnózisára
Dendle et al. Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
BR9815289A (pt) Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
TR199801722T2 (xx) Peptit imm�nojenler.
KR900013979A (ko) 사람 유두종비루스형 16의 e7 단백질상의 면역원성 영역
Guerino et al. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate
Pakkanen et al. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
Barral-Netto et al. Enzyme-linked immunosorbent assay for the detection of Bothrops jararaca venom
SE7809249L (sv) Antigen for tidig graviditetsprovning och kontraceptivt vaccin
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
Soppi et al. In vivo effect of levamisole on cellular and humoral immunity in normal chickens.
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
Yu et al. Development of a candidate vaccine against Ross River virus infection
Bošnjaković et al. Radiolabelled anti-human fibrin antibody: a new thrombus-detecting agent

Legal Events

Date Code Title Description
FG Grant, registration